tesamorelin + CJC-1295 + ipamorelin vs tesa+ipa blend

tesamorelin + CJC-1295 + ipamorelin (F-tier) vs tesa+ipa blend (A-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

tesamorelin + CJC-1295 + ipamorelin — tier F

a three-peptide GH-axis blend with no located direct study, whose CJC variant, component forms, and ratio must be known before even its duration can be described.

three characterized component mechanisms do not create a characterized product. until the CJC variant, tesamorelin formulation, ipamorelin form, and per-vial ratio are verified, the blend's PK and outcome claims stay blocked.

0 located fixed-blend studies · half-life blend unknown; 5.8 to 8.1 days belongs only to confirmed CJC-1295 with DAC · growth hormone

tesa+ipa blend — tier A

the GH-axis pairing built on the one GHRH leg that carries an FDA approval, tesamorelin, run alongside ipamorelin. the components are strong, the use is off-label, and the blend itself has no trial.

GHRH-plus-GHRP pharmacology where the GHRH half is the only one in its class with a full FDA approval. that approval covers HIV-associated visceral fat, not this blend and not this use.

1 of 2 FDA-approved GHRH leg · half-life tesamorelin: ~26-38 min (subQ); ipamorelin: ~2 h · growth hormone

at a glance

• tesamorelin + CJC-1295 + ipamorelin: tier F · 0 located fixed-blend studies
• tesa+ipa blend: tier A · 1 of 2 FDA-approved GHRH leg

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.